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impact of all therapies indicated for ultra-orphan disorders, which might be an 
important consideration for future models.  
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OBJECTIVES: The aim of this study is to estimate the development costs of a 
tailored intervention delivered via the interactive web, designed to increase 
cancer screening in women 51 to 75 who are non-adherent to colorectal cancer 
(CRC) and may or may not be adherent to breast cancer screening. METHODS: 
The cost of the intervention development is estimated from a societal 
perspective. Micro costing methods plus vendor contract costs were used to 
estimate the intervention development cost. Staff logs were used to track 
personnel time. Non-personnel costs include all resources used to produce the 
intervention. RESULTS: Development cost of the interactive web based 
intervention is $0.39 million, of which 77% is direct cost. About 98% of the cost 
was incurred in personnel time cost, contract cost and overhead cost. Eighteen 
persons contributed a total of 1610 hours to intervention development. 
CONCLUSIONS: The new web-based disease prevention medium requires 
substantial investment of health promotion and media specialist time. As health 
promotion and disease prevention programs move to the internet, it is important 
to assess development and intervention costs along with program impacts on 
health behaviors and outcomes. The cost of intervention development is 
important for planning future investments in web-based health promotion 
interventions and also relevant to the private sector investment and pricing 
decisions for new health promotion products and services.  
 
PCN31  
ADHERENCE TO AND COSTS OF LIFE EXTENDING THERAPIES FOR METASTATIC 
CASTRATE-RESISTANT PROSTATE CANCER  
Spalding J1, Bui CN1, Burton TM2 
1Astellas Pharma US, Inc., Northbrook, IL, USA, 2OptumInsight, Waltham, MA, USA  
OBJECTIVES: Life extending therapies (LETs) for metastatic castrate-resistant 
prostate cancer (mCRPC) increase overall survival. This study examined 
adherence to LETs and concomitant corticosteroids, and health care costs. 
METHODS: A retrospective claims study of commercial and Medicare Advantage 
enrollees with evidence of prostate cancer (ICD-9: 185.xx) between July 1, 2006 – 
June 30, 2011. mCRPC patients were identified based on evidence of LET use: 
docetaxel (DOC), cabazitaxel (CAB), and/or abiraterone acetate (ABI). The index 
date was the first date of chemotherapy. Patients were continuously enrolled for 
6 months before (baseline) and ≥6 months after the index date until December 
31, 2011 or death (follow-up). Adherence was defined as the proportion of days 
covered (PDC). Costs were the sum of health plan- and patient-paid amounts. 
Descriptive statistics summarized PDC and costs during follow-up. RESULTS: A 
total of 1,198 patients had ≥1 LET (DOC: 1,196, CAB: 27, ABI: 109). Mean±SD age 
was 69±9 years. Average PDC for LET was: DOC: 0.91, CAB: 0.88, ABI: 0.96. Half or 
more had a concomitant corticosteroid: DOC: 552, CAB: 17, ABI: 99, with an 
average PDC of: DOC 0.57, CAB 0.62, ABI 0.74. Average±SD cumulative 12-month 
health care costs were $76,550±$82,485. Average±SD per-patient-per-month 
(PPPM) health care costs during LET were higher for patients with a concomitant 
corticosteroid than those without: $9,307±$7,436 versus $5,929±$11,103; p<0.001. 
Patients with high adherence to a concomitant corticosteroid (PDC≥80%) had 
higher average PPPM costs during LET than patients with lower adherence 
(PDC<80%) or without: $9,028±$7,133 versus $7,339±$9,992; p=0.002. 
CONCLUSIONS: mCRPC patients had high adherence to LET but lower adherence 
to indicated concomitant corticosteroid. Average PPPM costs were higher for 
patients with greater adherence to concomitant corticosteroids than patients 
with lower adherence or no use. Multivariate analyses are planned to better 
understand the association between corticosteroid adherence during LET use 
and costs. The database timeframe did not allow for the inclusion of newer 
therapies.  
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OBJECTIVES: To estimate costs associated with adverse events (AEs) in patients 
aged ≥65 years receiving treatment for mRCC. METHODS: Retrospective study 
using the linked SEER (Surveillance, Epidemiology and End Results) Medicare 
database. Study subjects consisted of all persons in the linked SEER-Medicare 
database, aged ≥65 years, with evidence of newly diagnosed mRCC between 
January 1, 2007 and December 31, 2007. AEs of interest comprised abdominal 
pain, back pain, diarrhea, dyspnea, extremity pain, fatigue/asthenia, hand-foot 
syndrome, hypertension, lymphopenia, nausea/vomiting, neutropenia, and 
proteinuria. Patients receiving care for these AEs were identified using ICD-9-CM 
diagnosis codes on Medicare claims. Costs were examined over a 30-day period, 
beginning with date of first mention of each AE; non-evented patients were 
assigned a “shadow” index date for comparison purposes. We estimated total 
costs over 30 days following the index date for patients with and without AEs, on 
both an unadjusted basis and following adjustment for differences in baseline 
characteristics using a generalized linear model (GLM). RESULTS: Sixty percent of 
patients receiving treatment for mRCC had health care encounters for one or 
more AEs. Those occurring 20% or greater frequency included severe abdominal 
pain, dyspnea, and fatigue/asthenia; 10-20% of patients had encounters for back 
pain, extremity pain, and nausea/vomiting. Mean (SD) total costs of care during 
the 30-day, post-index period were substantially higher among patients with AEs 
($13,944 [$14,529] versus $1,878 [$5,264] for those without these events). 
Adjusting for differences in baseline characteristics, the estimated cost 
difference (95% CI) was $11,454 ($7,909 - $16,319). CONCLUSIONS: Costs of AEs 
associated with treatment of mRCC are high in patients aged ≥65 years. Efforts to 
prevent and/or better manage these events may reduce health care costs.  
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OBJECTIVES: As oral chemotherapy is becoming more prevalent in treating 
cancer patients, the cost difference between oral and conventional intravenous 
(IV) chemotherapy is not clear. The objective of this study was to compare the 
total costs of oral chemotherapy and IV chemotherapy in insured, low- income 
patients with breast cancer or colon cancer using South Carolina (S.C.) Medicaid 
claims data. METHODS: Patients with breast or colon cancer and receiving oral 
chemotherapy (capecitabine and oral cyslophosphamide) or conventional IV 
chemotherapy (5-FU and cyclophosphamide) were identified from S.C. Medicaid 
for years 2006-2009. Total costs, including inpatient, outpatient and prescription 
drugs, for one year follow-up period after initiation of chemotherapy were 
calculated. A multiple linear regression model with log transformation was used 
to examine the association between total costs and chemotherapy (oral vs. IV). 
RESULTS: A total of 1219 patients (857 for breast cancer, 362 for colon cancer) 
were identified from S.C. Medicaid claims data for years 2006-2009. The 
unadjusted annual total costs were $45,535(oral) and $59,498 (IV, p<0.001) for 
breast cancer, and $50,385 (oral) and $56,347 (IV, p=0.274) for colon cancer. Oral 
chemotherapy was associated with 36% and 43% reduction in cost for Medicaid 
breast and colon cancer patients respectively after adjusting for confounders. 
CONCLUSIONS: Total cost savings might be achieved in insured, low- income 
patients receiving oral chemotherapy to treat breast and colon cancers. Further 
studies are needed to link the costs to clinical outcomes and adverse drug events 
associated with chemotherapy.  
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OBJECTIVES: Chemotherapy induced nausea and vomiting (CINV) has clinical 
and economic implications. Controlling CINV upon chemotherapy initiation is 
important as the likelihood of CINV in future chemotherapy cycles increases if a 
patient experiences CINV in the first/previous chemotherapy cycle. The purpose 
of this study was to evaluate economic implications of 5-HT3-RA selection on 
CINV charges. METHODS: A retrospective analysis was conducted utilizing 
medical and pharmacy claims from 2005-2011 from a commercial (96%) and 
Medicaid (4%) population. Continuously enrolled patients (6 month pre-period, 6 
month post-period) with cancer receiving single-day chemotherapy regimens 
were eligible. Patients had to remain on initial 5-HT3-RA therapy and same level 
of emetic potential of chemotherapy throughout the study. CINV was defined as 
primary/secondary diagnosis of nausea, vomiting, or dehydration based on ICD-9 
codes, or use of rescue antiemetic medication. Charges for CINV were captured 
for an overall random sample of 1,000 for each chemotherapy cycle. A charge per 
patient was calculated and used to calculate an average charge for all patients in 
each 5-HT3-RA cohort based on the percentage of patients in each cycle 
experiencing CINV. Patients without CINV in the previous cycle or who switched 
5-HT3-RA therapy were excluded from subsequent calculations. RESULTS: 
Patients receiving palonosetron had lower rates of CINV across chemotherapy 
cycles compared to ondansetron, granisetron, or dolasetron. Patients receiving 
palonosetron had the lowest charges associated with CINV with a total of 
$300,293 over 6 cycles of chemotherapy. Patients receiving granisetron incurred 
the highest charges at $470,131 over 6 cycles. The use of palonosetron has the 
potential to result in a savings of $126,775 (vs ondansetron) to $169,838 (vs 
granisetron), depending on 5-HT3-RA selection. CONCLUSIONS: Patients 
receiving palonosetron experienced lower CINV-associated charges for each 
cycle of chemotherapy. Selection of 5-HT3-RA has the ability to positively impact 
economic outcomes associated with CINV.  
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OBJECTIVES: Radium-223 dichloride (Ra-223) is a novel alpha-
radiopharmaceutical, which delayed time to first skeletal-related event (SRE) and 
improved overall survival versus best standard of care (BSoC) in patients with 
symptomatic castration-resistant prostate cancer (mCRPC) with bone 
metastases. This analysis evaluated economic benefits associated with Ra-223. 
METHODS: A Markov model was developed using patient-level data from  
a pivotal trial in which mCRPC patients receiving BSoC were randomized 2:1 to 
